Certara (NASDAQ:CERT) Announces Earnings Results

Certara (NASDAQ:CERT - Get Free Report) released its earnings results on Wednesday. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02, Briefing.com reports. The business had revenue of $94.80 million for the quarter, compared to analyst estimates of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's revenue was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.06 earnings per share. Certara updated its FY24 guidance to $0.41-0.44 EPS and its FY 2024 guidance to 0.410-0.440 EPS.

Certara Trading Up 0.4 %

Shares of NASDAQ:CERT traded up $0.04 during midday trading on Friday, reaching $11.03. 1,081,810 shares of the company's stock were exchanged, compared to its average volume of 1,148,975. Certara has a fifty-two week low of $9.99 and a fifty-two week high of $19.87. The firm's 50 day simple moving average is $11.02 and its two-hundred day simple moving average is $13.70. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on CERT shares. Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research report on Tuesday. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Finally, Barclays dropped their price target on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Certara has an average rating of "Hold" and a consensus price target of $15.92.

Insider Activity

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the business's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the sale, the insider now owns 50,091 shares of the company's stock, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Certara news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares of the company's stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the transaction, the insider now owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.39% of the company's stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.